Samuel Wagner brings over two decades of leadership in health economics and outcomes research. He has held pivotal roles at multiple pharma companies, including BMS, where he built and led teams in predictive modeling and real-world evidence generation leveraging his deep experience in oncology and hematology.

Ted Witek served as former President and CEO of Boehringer Ingelheim Canada and sat on the Board of Directors of Innovative Medicines Canada. He is a Full Professor at the University of Toronto and has served on boards and committees, including the American Thoracic Society and the Ontario Health Innovation Council.

Eran Bendavid is an Associate Professor of Medicine at Stanford University. He specializes in the application of causal inference methods and population health in developing countries. His research explores the effects of economic, political, and natural environments on population health, with a clinical focus on Infectious Diseases.

Dr. Kelvin Chan, a medical oncologist at Sunnybrook Odette Cancer Centre and a professor at the University of Toronto, specializes in GI and head and neck oncology. His research spans health services, health technology assessment, and cost-effectiveness analyses, and he plays a key role in cancer drug reimbursement.

Dr. Darren Brenner is an Associate Professor and cancer epidemiologist at the University of Calgary. He focuses on the intersection of lifestyle, genetics, and molecular pathways in cancer development leading studies on biomarker utility in cancer risk prediction and the impact of lifestyle on molecular pathways in various cancers.

Rebecca Hancock Howard is an Adjunct Professor in health economics at the Institute for Health Policy, Management and Evaluation, University of Toronto. She leads independent consulting projects at the Accessing Centre for Expertise and serves as an advisory committee member on Ontario’s Committee to Evaluate Drugs. 

Dr. Audrey Beliveau, Assistant Professor at the University of Waterloo, specializes in Bayesian hierarchical modeling with applications in ecology and epidemiology. Her research integrates multiple data sources, emphasizing interdisciplinary collaborations in statistical ecology and network meta-analysis.

Emma Mackay, MA, MSc, is a statistician specializing in Bayesian methods. Her work has focused on applying Bayesian borrowing to address the challenges of evaluating efficacy in rare disease settings. She has extensive experience in survival modelling, synthetic control arms, and population-adjusted indirect comparisons.

Dr. Matthew Warkentin is a molecular epidemiologist with a decade of expertise in cancer research and machine learning. His work focuses on using big data and AI on medical images, for cancer detection and treatment. He advocates for open-source science and contributes to R and Python programming communities.

Dr. Daniel Harris is a Senior Research Scientist at Brown University School of Public Health with a strong background in pharmacoepidemiology. His research leverages claims data to explore drug utilization, safety, and effectiveness across large populations, employing multivariate statistics and machine learning.

Oscar Correa, Managing Partner and Director of Development at Eviviz, brings over 25 years of tech industry experience, focusing on client engagement and project management. His expertise lies in "Holistic Design" in information technology, emphasizing interconnected systems in real-life applications.

Dr. Anmol Arora is an Academic Foundation Doctor at Cambridge University Hospitals, specializing in artificial intelligence and machine learning in healthcare, particularly synthetic data. He holds honorary affiliations with NHS England and Improvement and Moorfields Eye Hospital, London, and has collaborated with institutions like Yale University.